Crimean-Congo Hemorrhagic Fever Virus: Current Advances and Future Prospects of Antiviral Strategies

Crimean-Congo hemorrhagic fever virus (CCHFV) is a widespread, tick-borne pathogen that causes Crimean-Congo hemorrhagic fever (CCHF) with high morbidity and mortality. CCHFV is transmitted to humans through tick bites or direct contact with patients or infected animals with viremia. Currently, clim...

Full description

Saved in:
Bibliographic Details
Published in:Viruses 2021-06, Vol.13 (7), p.1195
Main Authors: Dai, Shiyu, Deng, Fei, Wang, Hualin, Ning, Yunjia
Format: Article
Language:English
Subjects:
Antiviral agents
Antiviral drugs
antiviral strategies
bunyavirus
Climate change
Crimean hemorrhagic fever
Crimean-Congo hemorrhagic fever virus
Drugs
Fever
Hemorrhage
Infections
Infectious diseases
Interferon
Morbidity
Mortality
Proteins
Public health
Review
RNA polymerase
Severe acute respiratory syndrome coronavirus 2
tick-borne virus
Viral infections
Viremia
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Crimean-Congo hemorrhagic fever virus (CCHFV) is a widespread, tick-borne pathogen that causes Crimean-Congo hemorrhagic fever (CCHF) with high morbidity and mortality. CCHFV is transmitted to humans through tick bites or direct contact with patients or infected animals with viremia. Currently, climate change and globalization have increased the transmission risk of this biosafety level (BSL)-4 virus. The treatment options of CCHFV infection remain limited and there is no FDA-approved vaccine or specific antivirals, which urges the identification of potential therapeutic targets and the design of CCHF therapies with greater effort. In this article, we discuss the current progress and some future directions in the development of antiviral strategies against CCHFV.
ISSN:1999-4915
1999-4915
DOI:10.3390/v13071195